# Moderna and Merck say mRNA cancer vaccine cut death or recurrence risk by 42%

https://mins.news/en/item/111941

- Ars Technica, 2026-10-22 22:12 UTC
- Health
- Original: https://arstechnica.com/health/2026/10/personalized-mrna-cancer-vaccine-cut-melanoma-death-recurrence-by-42/

> Moderna and Merck said a late-stage trial found their personalized mRNA vaccine for melanoma reduced the risk of death or recurrence by 42% compared with standard treatment. The companies are in discussions with regulators about approval.

## Related coverage

- [Personalized mRNA melanoma vaccine cuts recurrence risk in late-stage trial](https://mins.news/en/item/113238) — NBC News, 2026-10-23
- [Novel mRNA cancer vaccine cuts melanoma recurrence risk in major study](https://mins.news/en/item/112975) — CBC News, 2026-10-23
- [Cancer vaccine lowers risk of melanoma tumors returning](https://mins.news/en/video/111892) — The Associated Press, 2026-10-22